Sign In
Buy NDAQ
$82.49
-0.120 (-0.145%)
At Close: Jun 23, 2026
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:00am, Thursday, 05'th Jun 2025
BRISBANE, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of pati
Bowman to Ring Nasdaq Opening Bell in Honor of 30th Anniversary
07:30am, Thursday, 05'th Jun 2025
RESTON, Va., June 05, 2025 (GLOBE NEWSWIRE) -- Bowman Consulting Group Ltd.
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:00am, Thursday, 05'th Jun 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for s
Australian Oilseeds Holdings Limited Announces Receipt of Nasdaq Notification Regarding Filing Delinquency
06:53pm, Wednesday, 04'th Jun 2025
COOTAMUNDRA, Australia, June 04, 2025 (GLOBE NEWSWIRE) -- Australian Oilseeds Holdings Limited (the “Company”) (NASDAQ: COOT), a manufacturer and seller of sustainable edible oils to customers glo
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
05:33pm, Wednesday, 04'th Jun 2025
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on June 2, 2025, the Compensation Committee of Puma's Board of Directors approved the
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05:00pm, Wednesday, 04'th Jun 2025
BOSTON, June 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for
Renatus Tactical Acquisition Corp I Announces the Separate Trading of Its Class A Ordinary Shares and Warrants, Commencing on June 9, 2025
04:05pm, Wednesday, 04'th Jun 2025
CORAL GABLES, Fla.--(BUSINESS WIRE)---- $RTAC #SPAC--Renatus Tactical Acquisition Corp I (Nasdaq: RTACU) (the “Company”) today announced that, commencing on June 9, 2025, holders of the units (the
Smith-Midland Announces Receipt of Nasdaq Letter
04:00pm, Wednesday, 04'th Jun 2025
MIDLAND, VA / ACCESS Newswire / June 4, 2025 / Smith-Midland Corporation (NASDAQ:SMID) (the "Company"), a provider of innovative, high-quality proprietary and patented precast concrete products and sy
Nasdaq Turns Positive in 2025: ETFs to Ride the Rally
12:01pm, Wednesday, 04'th Jun 2025
Nasdaq claws back gains in 2025 on AI-fueled tech strength and easing trade fears. ETFs like QQQ and QQQM ride the wave.
Nasdaq Launches Exclusive Access to Nasdaq Private Market's Tape D® API to Deliver Advanced Visibility into Private Markets
10:35am, Wednesday, 04'th Jun 2025
Real-Time Private Company Dataset Offers Critical Pricing and Valuation Insights for Private Companies, Investors, and Advisors Real-Time Private Company Dataset Offers Critical Pricing and Valuation
American Resources Corporation Featured in Nasdaq Amplify Issuer Spotlight
08:30am, Wednesday, 04'th Jun 2025
Reestablishing United States Dominance in the Critical Mineral Supply Chain FISHERS, IN / ACCESS Newswire / June 4, 2025 / American Resources Corporation (NASDAQ:AREC) ("American Resources"), a leader
Cognizant to Present at the Nasdaq Investor Conference in Partnership with Jefferies
08:00am, Wednesday, 04'th Jun 2025
TEANECK, N.J. , June 4, 2025 /PRNewswire/ -- Cognizant (Nasdaq: CTSH), a leading provider of information technology, consulting, and business process services, today announced a presentation at th
Helius Medical Technologies, Inc. Compliant with Nasdaq Bid Price Rule Listing Criteria
07:00am, Wednesday, 04'th Jun 2025
Company previously granted extension until June 30, 2025 to regain compliance with Nasdaq's Equity Rule requirement Company previously granted extension until June 30, 2025 to regain compliance with N
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Tuesday, 03'rd Jun 2025
SAN FRANCISCO, June 03, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, d
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Tuesday, 03'rd Jun 2025
WALTHAM, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies fo
